Codiak BioSciences, Inc.

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, VRTX has a market cap of 96.5B. Regarding current trading prices, CDAK is priced at $0.06, while VRTX trades at $385.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas VRTX's P/E ratio is 26.68. In terms of profitability, CDAK's ROE is -1.22%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, CDAK is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check VRTX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, REGN has a market cap of 58.3B. Regarding current trading prices, CDAK is priced at $0.06, while REGN trades at $555.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas REGN's P/E ratio is 14.10. In terms of profitability, CDAK's ROE is -1.22%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CDAK is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check REGN's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ALNY has a market cap of 57B. Regarding current trading prices, CDAK is priced at $0.06, while ALNY trades at $428.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ALNY's P/E ratio is -176.15. In terms of profitability, CDAK's ROE is -1.22%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, CDAK is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ALNY's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CDAK is priced at $0.06, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CDAK's ROE is -1.22%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CDAK is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check SGEN's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ARGX has a market cap of 41.1B. Regarding current trading prices, CDAK is priced at $0.06, while ARGX trades at $673.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ARGX's P/E ratio is 34.20. In terms of profitability, CDAK's ROE is -1.22%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, CDAK is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ARGX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, BNTX has a market cap of 26.8B. Regarding current trading prices, CDAK is priced at $0.06, while BNTX trades at $111.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas BNTX's P/E ratio is -67.48. In terms of profitability, CDAK's ROE is -1.22%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, CDAK is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check BNTX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, SMMT has a market cap of 20.8B. Regarding current trading prices, CDAK is priced at $0.06, while SMMT trades at $28.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas SMMT's P/E ratio is -82.56. In terms of profitability, CDAK's ROE is -1.22%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, CDAK is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check SMMT's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RPRX has a market cap of 20.8B. Regarding current trading prices, CDAK is priced at $0.06, while RPRX trades at $37.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RPRX's P/E ratio is 16.16. In terms of profitability, CDAK's ROE is -1.22%, compared to RPRX's ROE of +0.14%. Regarding short-term risk, CDAK is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RPRX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CDAK is priced at $0.06, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CDAK's ROE is -1.22%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, CDAK is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check BGNE's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CDAK is priced at $0.06, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CDAK's ROE is -1.22%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, CDAK is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check DNA-WT's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, INCY has a market cap of 15.3B. Regarding current trading prices, CDAK is priced at $0.06, while INCY trades at $77.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas INCY's P/E ratio is 18.49. In terms of profitability, CDAK's ROE is -1.22%, compared to INCY's ROE of +0.34%. Regarding short-term risk, CDAK is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check INCY's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, GMAB has a market cap of 14B. Regarding current trading prices, CDAK is priced at $0.06, while GMAB trades at $21.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas GMAB's P/E ratio is 13.35. In terms of profitability, CDAK's ROE is -1.22%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, CDAK is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check GMAB's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, UTHR has a market cap of 13.5B. Regarding current trading prices, CDAK is priced at $0.06, while UTHR trades at $302.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas UTHR's P/E ratio is 11.68. In terms of profitability, CDAK's ROE is -1.22%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CDAK is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check UTHR's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CDAK is priced at $0.06, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CDAK's ROE is -1.22%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CDAK is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check KRTX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ASND has a market cap of 11.5B. Regarding current trading prices, CDAK is priced at $0.06, while ASND trades at $182.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ASND's P/E ratio is -28.24. In terms of profitability, CDAK's ROE is -1.22%, compared to ASND's ROE of +1.91%. Regarding short-term risk, CDAK is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ASND's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, CDAK is priced at $0.06, while BMRN trades at $60.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas BMRN's P/E ratio is 17.54. In terms of profitability, CDAK's ROE is -1.22%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, CDAK is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check BMRN's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MRNA has a market cap of 10.4B. Regarding current trading prices, CDAK is priced at $0.06, while MRNA trades at $26.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MRNA's P/E ratio is -3.54. In terms of profitability, CDAK's ROE is -1.22%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, CDAK is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MRNA's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, EXEL has a market cap of 10.1B. Regarding current trading prices, CDAK is priced at $0.06, while EXEL trades at $37.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas EXEL's P/E ratio is 17.98. In terms of profitability, CDAK's ROE is -1.22%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, CDAK is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check EXEL's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CDAK is priced at $0.06, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CDAK's ROE is -1.22%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CDAK is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RXDX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, CDAK is priced at $0.06, while VRNA trades at $105.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas VRNA's P/E ratio is -52.70. In terms of profitability, CDAK's ROE is -1.22%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, CDAK is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check VRNA's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, CDAK is priced at $0.06, while BBIO trades at $44.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas BBIO's P/E ratio is -11.13. In terms of profitability, CDAK's ROE is -1.22%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, CDAK is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check BBIO's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CDAK is priced at $0.06, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CDAK's ROE is -1.22%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, CDAK is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check IMGN's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CDAK is priced at $0.06, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CDAK's ROE is -1.22%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, CDAK is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check BPMC's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CDAK is priced at $0.06, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CERE's P/E ratio is -16.47. In terms of profitability, CDAK's ROE is -1.22%, compared to CERE's ROE of -0.43%. Regarding short-term risk, CDAK is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CERE's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, TECH has a market cap of 7.9B. Regarding current trading prices, CDAK is priced at $0.06, while TECH trades at $49.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas TECH's P/E ratio is 109.02. In terms of profitability, CDAK's ROE is -1.22%, compared to TECH's ROE of +0.06%. Regarding short-term risk, CDAK is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check TECH's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, CDAK is priced at $0.06, while ROIV trades at $11.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ROIV's P/E ratio is -15.40. In terms of profitability, CDAK's ROE is -1.22%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, CDAK is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ROIV's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, CDAK is priced at $0.06, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, CDAK's ROE is -1.22%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, CDAK is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ROIVW's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MDGL has a market cap of 7.6B. Regarding current trading prices, CDAK is priced at $0.06, while MDGL trades at $338.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MDGL's P/E ratio is -27.06. In terms of profitability, CDAK's ROE is -1.22%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, CDAK is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MDGL's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CORT has a market cap of 7.5B. Regarding current trading prices, CDAK is priced at $0.06, while CORT trades at $70.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CORT's P/E ratio is 63.82. In terms of profitability, CDAK's ROE is -1.22%, compared to CORT's ROE of +0.20%. Regarding short-term risk, CDAK is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CORT's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, HALO has a market cap of 7.3B. Regarding current trading prices, CDAK is priced at $0.06, while HALO trades at $62.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas HALO's P/E ratio is 14.21. In terms of profitability, CDAK's ROE is -1.22%, compared to HALO's ROE of +1.37%. Regarding short-term risk, CDAK is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check HALO's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, JAZZ has a market cap of 6.8B. Regarding current trading prices, CDAK is priced at $0.06, while JAZZ trades at $105.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas JAZZ's P/E ratio is -16.06. In terms of profitability, CDAK's ROE is -1.22%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, CDAK is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check JAZZ's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CDAK is priced at $0.06, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RETA's P/E ratio is -66.29. In terms of profitability, CDAK's ROE is -1.22%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CDAK is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RETA's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, IONS has a market cap of 6.5B. Regarding current trading prices, CDAK is priced at $0.06, while IONS trades at $40.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas IONS's P/E ratio is -23.32. In terms of profitability, CDAK's ROE is -1.22%, compared to IONS's ROE of -0.45%. Regarding short-term risk, CDAK is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check IONS's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RVMD has a market cap of 6.5B. Regarding current trading prices, CDAK is priced at $0.06, while RVMD trades at $36.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RVMD's P/E ratio is -8.72. In terms of profitability, CDAK's ROE is -1.22%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, CDAK is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RVMD's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, CDAK is priced at $0.06, while RYTM trades at $90.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RYTM's P/E ratio is -30.72. In terms of profitability, CDAK's ROE is -1.22%, compared to RYTM's ROE of -2.26%. Regarding short-term risk, CDAK is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RYTM's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RNA has a market cap of 5.7B. Regarding current trading prices, CDAK is priced at $0.06, while RNA trades at $48.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RNA's P/E ratio is -15.84. In terms of profitability, CDAK's ROE is -1.22%, compared to RNA's ROE of -0.27%. Regarding short-term risk, CDAK is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RNA's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CDAK is priced at $0.06, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CDAK's ROE is -1.22%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CDAK is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ABCM's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CDAK is priced at $0.06, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CDAK's ROE is -1.22%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CDAK is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ISEE's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ABVX has a market cap of 5.3B. Regarding current trading prices, CDAK is priced at $0.06, while ABVX trades at $69.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ABVX's P/E ratio is -20.47. In terms of profitability, CDAK's ROE is -1.22%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, CDAK is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ABVX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, CDAK is priced at $0.06, while AXSM trades at $103.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas AXSM's P/E ratio is -20.62. In terms of profitability, CDAK's ROE is -1.22%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, CDAK is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check AXSM's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, NUVL has a market cap of 5.2B. Regarding current trading prices, CDAK is priced at $0.06, while NUVL trades at $77.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas NUVL's P/E ratio is -16.33. In terms of profitability, CDAK's ROE is -1.22%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, CDAK is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check NUVL's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, CDAK is priced at $0.06, while CRSP trades at $56.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CRSP's P/E ratio is -10.36. In terms of profitability, CDAK's ROE is -1.22%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, CDAK is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CRSP's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MRUS has a market cap of 4.8B. Regarding current trading prices, CDAK is priced at $0.06, while MRUS trades at $65.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MRUS's P/E ratio is -11.36. In terms of profitability, CDAK's ROE is -1.22%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, CDAK is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MRUS's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CDAK is priced at $0.06, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CDAK's ROE is -1.22%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CDAK is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ALPN's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, TGTX has a market cap of 4.4B. Regarding current trading prices, CDAK is priced at $0.06, while TGTX trades at $27.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas TGTX's P/E ratio is 73.39. In terms of profitability, CDAK's ROE is -1.22%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, CDAK is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check TGTX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, CDAK is priced at $0.06, while ALKS trades at $26.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ALKS's P/E ratio is 12.85. In terms of profitability, CDAK's ROE is -1.22%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, CDAK is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ALKS's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CYTK has a market cap of 4.2B. Regarding current trading prices, CDAK is priced at $0.06, while CYTK trades at $35.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CYTK's P/E ratio is -6.66. In terms of profitability, CDAK's ROE is -1.22%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, CDAK is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CYTK's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CDAK is priced at $0.06, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas OPT's P/E ratio is -1.52. In terms of profitability, CDAK's ROE is -1.22%, compared to OPT's ROE of +2.60%. Regarding short-term risk, CDAK is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check OPT's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, SLNO has a market cap of 4.2B. Regarding current trading prices, CDAK is priced at $0.06, while SLNO trades at $81.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas SLNO's P/E ratio is -16.61. In terms of profitability, CDAK's ROE is -1.22%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, CDAK is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check SLNO's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CDAK is priced at $0.06, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CDAK's ROE is -1.22%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CDAK is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MRTX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ACAD has a market cap of 4.1B. Regarding current trading prices, CDAK is priced at $0.06, while ACAD trades at $23.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ACAD's P/E ratio is 17.81. In terms of profitability, CDAK's ROE is -1.22%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, CDAK is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ACAD's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, CDAK is priced at $0.06, while AKRO trades at $52.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas AKRO's P/E ratio is -13.43. In terms of profitability, CDAK's ROE is -1.22%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, CDAK is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check AKRO's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, AAPG has a market cap of 4B. Regarding current trading prices, CDAK is priced at $0.06, while AAPG trades at $42.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas AAPG's P/E ratio is -57.72. In terms of profitability, CDAK's ROE is -1.22%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, CDAK is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check AAPG's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ADMA has a market cap of 4B. Regarding current trading prices, CDAK is priced at $0.06, while ADMA trades at $18.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ADMA's P/E ratio is 19.94. In terms of profitability, CDAK's ROE is -1.22%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, CDAK is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ADMA's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, CDAK is priced at $0.06, while VKTX trades at $31.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas VKTX's P/E ratio is -23.09. In terms of profitability, CDAK's ROE is -1.22%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, CDAK is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check VKTX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, PTCT has a market cap of 4B. Regarding current trading prices, CDAK is priced at $0.06, while PTCT trades at $51.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas PTCT's P/E ratio is 7.74. In terms of profitability, CDAK's ROE is -1.22%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, CDAK is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check PTCT's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, TLX has a market cap of 4B. Regarding current trading prices, CDAK is priced at $0.06, while TLX trades at $11.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas TLX's P/E ratio is 130.89. In terms of profitability, CDAK's ROE is -1.22%, compared to TLX's ROE of +0.06%. Regarding short-term risk, CDAK is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check TLX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, KRYS has a market cap of 3.9B. Regarding current trading prices, CDAK is priced at $0.06, while KRYS trades at $136.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas KRYS's P/E ratio is 27.66. In terms of profitability, CDAK's ROE is -1.22%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, CDAK is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check KRYS's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, CDAK is priced at $0.06, while ACLX trades at $70.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ACLX's P/E ratio is -23.83. In terms of profitability, CDAK's ROE is -1.22%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, CDAK is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ACLX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, PCVX has a market cap of 3.9B. Regarding current trading prices, CDAK is priced at $0.06, while PCVX trades at $33.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas PCVX's P/E ratio is -7.52. In terms of profitability, CDAK's ROE is -1.22%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, CDAK is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check PCVX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, CDAK is priced at $0.06, while ZLAB trades at $38.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ZLAB's P/E ratio is -13.63. In terms of profitability, CDAK's ROE is -1.22%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, CDAK is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ZLAB's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CDAK is priced at $0.06, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CDAK's ROE is -1.22%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CDAK is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RYZB's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CDAK is priced at $0.06, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CDAK's ROE is -1.22%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CDAK is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CBAY's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CDAK is priced at $0.06, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CDAK's ROE is -1.22%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, CDAK is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check SWTX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, CDAK is priced at $0.06, while LEGN trades at $37.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas LEGN's P/E ratio is -31.72. In terms of profitability, CDAK's ROE is -1.22%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, CDAK is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check LEGN's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MLTX has a market cap of 3.3B. Regarding current trading prices, CDAK is priced at $0.06, while MLTX trades at $52.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MLTX's P/E ratio is -18.60. In terms of profitability, CDAK's ROE is -1.22%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, CDAK is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MLTX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MTSR has a market cap of 3.2B. Regarding current trading prices, CDAK is priced at $0.06, while MTSR trades at $33.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MTSR's P/E ratio is -10.54. In terms of profitability, CDAK's ROE is -1.22%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, CDAK is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MTSR's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, PTGX has a market cap of 3.2B. Regarding current trading prices, CDAK is priced at $0.06, while PTGX trades at $53.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas PTGX's P/E ratio is 65.33. In terms of profitability, CDAK's ROE is -1.22%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, CDAK is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check PTGX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, APLS has a market cap of 3.1B. Regarding current trading prices, CDAK is priced at $0.06, while APLS trades at $23.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas APLS's P/E ratio is -13.32. In terms of profitability, CDAK's ROE is -1.22%, compared to APLS's ROE of -1.16%. Regarding short-term risk, CDAK is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check APLS's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, SRRK has a market cap of 3B. Regarding current trading prices, CDAK is priced at $0.06, while SRRK trades at $34.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas SRRK's P/E ratio is -10.75. In terms of profitability, CDAK's ROE is -1.22%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, CDAK is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check SRRK's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MIRM has a market cap of 3B. Regarding current trading prices, CDAK is priced at $0.06, while MIRM trades at $53.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MIRM's P/E ratio is -37.16. In terms of profitability, CDAK's ROE is -1.22%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, CDAK is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MIRM's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, CDAK is priced at $0.06, while KYMR trades at $41.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas KYMR's P/E ratio is -13.14. In terms of profitability, CDAK's ROE is -1.22%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, CDAK is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check KYMR's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, CDAK is priced at $0.06, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MORF's P/E ratio is -14.88. In terms of profitability, CDAK's ROE is -1.22%, compared to MORF's ROE of -0.22%. Regarding short-term risk, CDAK is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MORF's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, CDAK is priced at $0.06, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MOR's P/E ratio is -12.64. In terms of profitability, CDAK's ROE is -1.22%, compared to MOR's ROE of -1.84%. Regarding short-term risk, CDAK is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MOR's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, LGND has a market cap of 2.8B. Regarding current trading prices, CDAK is priced at $0.06, while LGND trades at $142.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas LGND's P/E ratio is -20.10. In terms of profitability, CDAK's ROE is -1.22%, compared to LGND's ROE of -0.16%. Regarding short-term risk, CDAK is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check LGND's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, CDAK is priced at $0.06, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas KDNY's P/E ratio is -12.47. In terms of profitability, CDAK's ROE is -1.22%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, CDAK is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check KDNY's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, CDAK is priced at $0.06, while IMVT trades at $15.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas IMVT's P/E ratio is -5.76. In terms of profitability, CDAK's ROE is -1.22%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, CDAK is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check IMVT's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, CDAK is priced at $0.06, while RARE trades at $28.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RARE's P/E ratio is -5.08. In terms of profitability, CDAK's ROE is -1.22%, compared to RARE's ROE of -2.37%. Regarding short-term risk, CDAK is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RARE's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, CDAK is priced at $0.06, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas MYOV's P/E ratio is -14.05. In terms of profitability, CDAK's ROE is -1.22%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, CDAK is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check MYOV's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CRNX has a market cap of 2.6B. Regarding current trading prices, CDAK is priced at $0.06, while CRNX trades at $28.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CRNX's P/E ratio is -7.34. In terms of profitability, CDAK's ROE is -1.22%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, CDAK is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CRNX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, XENE has a market cap of 2.6B. Regarding current trading prices, CDAK is priced at $0.06, while XENE trades at $34.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas XENE's P/E ratio is -10.44. In terms of profitability, CDAK's ROE is -1.22%, compared to XENE's ROE of -0.32%. Regarding short-term risk, CDAK is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check XENE's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, NAMS has a market cap of 2.6B. Regarding current trading prices, CDAK is priced at $0.06, while NAMS trades at $23.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas NAMS's P/E ratio is -14.44. In terms of profitability, CDAK's ROE is -1.22%, compared to NAMS's ROE of -0.22%. Regarding short-term risk, CDAK is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check NAMS's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, CDAK is priced at $0.06, while KNSA trades at $32.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas KNSA's P/E ratio is 662.20. In terms of profitability, CDAK's ROE is -1.22%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, CDAK is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check KNSA's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, NAMSW has a market cap of 2.4B. Regarding current trading prices, CDAK is priced at $0.06, while NAMSW trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CDAK's ROE is -1.22%, compared to NAMSW's ROE of -0.22%. Regarding short-term risk, CDAK is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check NAMSW's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CPRX has a market cap of 2.4B. Regarding current trading prices, CDAK is priced at $0.06, while CPRX trades at $21.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CPRX's P/E ratio is 12.51. In terms of profitability, CDAK's ROE is -1.22%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, CDAK is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CPRX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, CDAK is priced at $0.06, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas PRVB's P/E ratio is -16.43. In terms of profitability, CDAK's ROE is -1.22%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, CDAK is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check PRVB's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, CDAK is priced at $0.06, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas LBPH's P/E ratio is -26.66. In terms of profitability, CDAK's ROE is -1.22%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, CDAK is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check LBPH's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, RXRX has a market cap of 2.3B. Regarding current trading prices, CDAK is priced at $0.06, while RXRX trades at $5.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas RXRX's P/E ratio is -2.99. In terms of profitability, CDAK's ROE is -1.22%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, CDAK is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check RXRX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, CDAK is priced at $0.06, while CNTA trades at $17.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CNTA's P/E ratio is -9.14. In terms of profitability, CDAK's ROE is -1.22%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, CDAK is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CNTA's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, BLTE has a market cap of 2.3B. Regarding current trading prices, CDAK is priced at $0.06, while BLTE trades at $67.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas BLTE's P/E ratio is -51.54. In terms of profitability, CDAK's ROE is -1.22%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, CDAK is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check BLTE's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, CDAK is priced at $0.06, while IBRX trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas IBRX's P/E ratio is -5.01. In terms of profitability, CDAK's ROE is -1.22%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, CDAK is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check IBRX's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, CDAK is priced at $0.06, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas DICE's P/E ratio is -21.91. In terms of profitability, CDAK's ROE is -1.22%, compared to DICE's ROE of +0.56%. Regarding short-term risk, CDAK is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check DICE's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, CDAK is priced at $0.06, while ARWR trades at $16.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas ARWR's P/E ratio is -12.95. In terms of profitability, CDAK's ROE is -1.22%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, CDAK is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check ARWR's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, VCYT has a market cap of 2.2B. Regarding current trading prices, CDAK is priced at $0.06, while VCYT trades at $23.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas VCYT's P/E ratio is 65.90. In terms of profitability, CDAK's ROE is -1.22%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, CDAK is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check VCYT's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, CDAK is priced at $0.06, while GLPG trades at $32.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas GLPG's P/E ratio is -6.49. In terms of profitability, CDAK's ROE is -1.22%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, CDAK is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check GLPG's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, CDAK is priced at $0.06, while AGIO trades at $37.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas AGIO's P/E ratio is 3.28. In terms of profitability, CDAK's ROE is -1.22%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, CDAK is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check AGIO's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, CDAK is priced at $0.06, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas CALT's P/E ratio is -22.73. In terms of profitability, CDAK's ROE is -1.22%, compared to CALT's ROE of -1.67%. Regarding short-term risk, CDAK is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check CALT's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, APGE has a market cap of 2.1B. Regarding current trading prices, CDAK is priced at $0.06, while APGE trades at $36.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas APGE's P/E ratio is -9.97. In terms of profitability, CDAK's ROE is -1.22%, compared to APGE's ROE of -0.19%. Regarding short-term risk, CDAK is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check APGE's competition here

CDAK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CDAK stands at 0. In comparison, OCUL has a market cap of 2.1B. Regarding current trading prices, CDAK is priced at $0.06, while OCUL trades at $12.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CDAK currently has a P/E ratio of -0.12, whereas OCUL's P/E ratio is -9.76. In terms of profitability, CDAK's ROE is -1.22%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, CDAK is more volatile compared to OCUL. This indicates potentially higher risk in terms of short-term price fluctuations for CDAK.Check OCUL's competition here